Willenken’s managing partner and trial lawyer, Paul Loh is honored to be selected by Daily Journal to the notable 2024 “Leading Commercial Litigators” list.
In the second edition of Daily Journal‘s Leading Commercial Litigation issue, the publication honors the best commercial and bet-the-company litigators across the country. Paul has tried more than 120 jury trials, court trials, and arbitrations during his impressive career.
The Daily Journal highlights Paul‘s extensive trial expertise, including a recent significant win for AbbVie in a high-stakes trial against Takeda about a breach of a pharmaceutical supply contract.
“The matter was significant not only because of the complex, high financial stakes, but because it also concerns a critical, life-extending cancer drug, Lupron, which is the gold standard for the treatment of advanced prostate cancer,” Paul said about the AbbVie case.
“We are particularly honored and proud that this sizable judgment was obtained by a 100% minority-owned law firm and the trial team was 100% diverse,” Paul said about the remarkable verdict in favor of AbbVie in excess of $490 million.
To read Daily Journal’s 2024 Leading Commercial Litigators profile on Paul, click here.
